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resulting incremental cost per QALY of 7721 demonstrated
that maintenance therapy with rituximab when compared to
observation was cost-effective. The cost per QALY was very
robust when subject to extensive one-way and probabilistic sen-
sitivity analysis. Probabilistic sensitivity analyses indicated that
the likelihood of the ICER being below 10,000 was 90%.
CONCLUSION: From the perspective of UK NHS, maintenance
rituximab when compared to observation alone for the treatment
of relapsed/refractory follicular NHL patients responding to
induction therapy is a highly cost-effective treatment.
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OBJECTIVES: In Hungary the standard therapy in the adjuvant
treatment of stage III colon cancer is the DeGramont-protocol, a
combination of 5-ﬂuorouracil and leucovorin. In the MOSAIC
trial the addition of oxaliplatin (FOLFOX4) improved the efﬁcacy
of the standard therapy in this patient group. The aim of our study
was to evaluate the cost-effectiveness of FOLFOX4 compared to
standard therapy in Hungary.METHODS: The cost-utility analy-
sis of the FOLFOX4 therapy was based on theMOSAIC trial. The
efﬁcacy data of the MOSAIC trial was extrapolated for lifetime,
while utilities values were incorporated from published sources.
Age and gender speciﬁc general mortality rates and utilities were
derived from epidemiology data of the Hungarian population and
published utilities based on the EQ-5D questionnaire. The analy-
sis was accomplished from payer perspective. Thus, only direct
medical costs were taken into account. Resource use was based on
Hungarian treatment patterns and unit costs. Costs and outcomes
were discounted at 5%. Cost-effectiveness was measured in terms
of incremental cost per quality-adjusted life year saved (QALY),
incremental cost per disease-free years (DFY) and incremental
cost per life-years saved (LYS). One-way sensitivity analysis
was employed. RESULTS: Compared to DeGramont therapy,
FOLFOX4 resulted in an additional 0.455 QALY, 0.531 LYS,
0.958 DFY andHUF 1,310,064 (5,240€) per patient. The cost for
one QALY was HUF 2,880,342 (11,521€), while for one DFS and
LYS was HUF 1,367,712 (5,471€) and HUF 2,468,660 (9,875€),
respectively. The results were most sensitive to discount rate,
general population data and the cost of chemotherapy.CONCLU-
SION: Based on the possible thresholds in Hungary, and the
€20,000/QALY quoted in countries of the EU zone, FOLFOX4 is
a cost-effective strategy inHungary for the postoperative adjuvant
treatment of patients with stage III colon cancer compared to the
DeGramont protocol.
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OBJECTIVES: The aim of the study was to analyze the cost-
effectiveness of sunitinib malate, a novel cancer treatment, as a
second-line therapy for metastatic renal cell carcinoma (mRCC)
after ﬁrst-line cytokine treatment compared with current Finnish
treatment practice. Cytokine therapy is currently the standard
ﬁrst line treatment for mRCC. Until recently, treatments with
proven efﬁcacy after the failure of ﬁrst line cytokine therapy have
not been available. METHODS: Information for analyses was
gathered from clinical trials, the literature and patient records
from two Finnish university hospitals. Clinical experts treating
mRCC-patients in Finland provided the information on current
practices for the sunitinib treatment. A comprehensive probabi-
listic decision-analytic model was developed using WinBUGS
software to estimate the cost-effectiveness and expected value
of perfect information (EVPI) of sunitinib malate. An EVPI
approach was used to estimate the expected costs of decision
uncertainty. A societal perspective was assumed in all analyses to
avoid suboptimal decisions. RESULTS: The Kaplan-Meier sur-
vival estimates after cytokine failure for local patients (n = 39)
were 3.8 months (95% CI, 2.16–5.51) and 1.4 months (95% CI,
0.7–2.17) for overall and progression-free survival, respectively.
When compared to the current Finnish treatment practice, suni-
tinib prolonged life expectancy by 1 year and resulted in a
progression-free time of 6.3 months and in 0.7 QALYs gained.
Over a ﬁve-year time period, an incremental cost-effectiveness
ratio (ICER) of 42,877€ per QALY was obtained. Sunitinib was
estimated to have an 88% probability of being cost-effective at
the willingness-to-pay level of 45,000€/QALY. The population
EVPI for the decision between sunitinib-treatment and current
Finnish treatment practice was 607,000€ at a willingness-to-pay
level of 42,500€. CONCLUSION: Sunitinib malate results in
improved survival and is potentially cost-effective as a second-
line treatment of mRCC compared to the current clinical practice
used in Finnish hospitals.
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OBJECTIVES: Maintenance therapy with rituximab has shown
signiﬁcant improvements in overall survival and progression-free
survival (PFS) when compared with observation in patients with
relapsed/refractory follicular lymphoma (van Oers et al., 2006).
The primary objective of this analysis was to estimate the incre-
mental cost-efectiveness ratio (ICER) of rituximab maintenance
therapy versus observation alone, based on data from the
EORTC 20981 study. METHODS: Rituximab maintenance
therapy (375 mg/m2 every 3 months) was evaluated using a
Markov model. All patients entered in the model following
response to CHOP chemotherapy +/- rituximab as induction
therapy. PFS and Overall Survival (OS) following rituximab
maintenance were extrapolated from 2-year Kaplan-Meier
curves from the study data using a parametric approach. Cox-
Snell and deviance residuals were analysed. Quality-of-life utility
values were derived from a study of 165 patients using the
EQ-5D questionnaire. Direct annual medical costs including
adverse events, drug acquisition, administration and preparation
were estimated accordingly to a Delphi panel with Brazilian
haematologists. Costs were reported in 2007 Brazilian Reais.
Both costs and outcomes were discounted at 3.5% rate according
to NICE/UK recommendation. In order to assess uncertainty,
probabilistic sensitivity analyses were also performed. A lifetime
horizon and a payer perspective in Brazil were adopted.
RESULTS: Rituximab maintenance resulted in a gain of 1.79
QALYs (5.96 vs. 4.17) at an incremental cost of R$57,595 The
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ICER of rituximab maintenance vs. observation alone is, there-
fore, estimated to be R$32,236 per QALY gained. The ICER of
rituximab maintenance was sensitive to the duration of treatment
beneﬁt, discount rate and drug cost. CONCLUSION: In patients
responding to induction therapy, rituximab maintenance therapy
improves overall survival and progression-free survival com-
pared with observation alone. Results suggest that maintenance
therapy with rituximab is a cost-effective intervention for the
management of patients with follicular lymphoma in the Brazil-
ian Private Healthcare System.
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OBJECTIVES: The goal of research was to investigate the cost
of DRG based anti-cancer chemotherapies. Costs for investi-
gated chemotherapies have been allocated to oncology centers
from the budget of National Heath Fund Administration, based
on DRG-reimbursement. METHODS: Cost analysis of chemo-
therapy protocols has been conducted, from the perspective of
National Heath Fund Administration, focusing on cost of medi-
cation, hospitalisation and the total expenditure of protocols.
RESULTS: The standard process of protocol-expenditure calcu-
lation has been identiﬁed. The drug related cost has been based
on the ex-factory prices of medicines. Expenditures of hospi-
talisation have been calculated on the days of total length of
drug administration and not on term of hospitalisation. Che-
motherapies, containing per os anti-cancer medication have
been found over-charged. The cost ratio of oral drug and pro-
tocol expenses has been found lower than the average of oncol-
ogy protocols, from 1,75 to 26.9%. Consequetly, the cost of
hospitalisaton has been over-represented in these protocolls,
although these treatments have reqired less hospitalisation.
Using per os chemotherapy protocols has resulted idle capacity
in utilization of protocol-expenditures. CONCLUSION: The
cost of hospitalisation based on “days of treatment” hasn’t
reﬂected correctly the occurrent expenses. Per os chemothera-
pies alone should have been reimbursed as outpatient care and
not involved into DRG based hospital care. The cost of proto-
cols, containing per os and i.v. compounds in combination
should have been calculated on a real-cost basis, considering
the days of hospitalisation.
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OBJECTIVES: To calculate the burden of cancer in the private
and public healthc care sector, compare it to the health care
resources consumed, and to other disease areas. Ultimately we
seek to understand whether scarce health care resource allocation
is optimally distributed between different diseases. METHODS:
We ﬁrst attempted to calculate the burden of cancer for South
Africa using Statistics SA, South African death registry and the
National Cancer Registry data. Using different data sets we then
differentiated the data in order to estimate the public and private
sector burden of cancer. By using the latest South African
National Health Accounts and medical insurance data, we then
calculated the direct monetary health care resources for cancer
and other diseases. Lastly we attempted to calculate the indirect
costs associated with cancer and other diseases using the human
capital methodology. We were able to compare burden of cancer,
cardiovascular disease, diabetes, HIV/AIDS, injuries, mental
disease, respiratory disease and all other diseases to the direct
monetary health care resources as well as the indirect costs
associated with disease. RESULTS: HIV/AIDS and injuries con-
tributed 30.9% and 14.3% to the burden of disease in South
Africa while cancer was 3.1%. When comparing the direct health
care cost as a percentage of total health care spending to the
cancer DALY as a percentage of total DALY, the ratio was 1.07.
This indicates that, from a direct health care cost perspective,
direct health care cost consumption was proportionate to the
burden. However, when comparing direct health care cost per-
centage to indirect costs percentage, the ratio for cancer is 0.36.
Similar results were seen in the public and private sector. CON-
CLUSION: From a societal perspective, it appears that too little
resources are allocated to cancer and some other chronic diseases
in South Africa.
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OBJECTIVES: The aim of this study is to compare the distri-
bution of health insurance treatment cost of and mortality due
to cervical cancer according to age-groups. METHODS: Data
derive from the database of the National Health Insurance Fund
Administration (OEP) containing routinely collected ﬁnancial
data. The study includes all the women who received outpatient
and/or inpatient care treatment in 2001 ﬁnanced from public
resources of OEP. Number of deaths due to cervical cancer is
from the Central Statistical Ofﬁce database. We compared the
annual out- and inpatient care treatment cost and the annual
number of deaths according to age groups. RESULTS: The cost
distribution of out- and inpatient care treatment cost of cervical
cancer was the following (outp./inp.): 0–24 years: 0.2%/0.2%;
25–44 years: 33.2%/35.8%; 45–64 years: 47.2%/47.3%; 65–74
years: 12.9%/13.2%; 75 and over: 6.5%/3.6%. The distribu-
tion of deaths due to cervical cancer was the following: 0–24
years: 0.0%; 25–44 years: 16.3%; 45–64 years: 41.0%; 65–74
years: 21.7%; 75 and over: 21.0%. Summarizing these
numbers, women aged 0–64 years accounts for 57.3% of all
deaths due to cervical cancer but they received 80.6% and
83.3% of treatment cost of in- and outpatient care. While
women aged 65 or over accounts for 42.7% of deaths and
consumed only 19.4% and 16.7% of of treatment cost of in-
and outpatient care. CONCLUSION: Women in younger age
groups received more treatment cost than its mortality would
predict, while women in older age groups received less treat-
ment cost of out- and inpatient care. There is a shift between
the distribution of treatment cost of and deaths due to cervical
cancer in favor of younger age-groups.
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